125 related articles for article (PubMed ID: 15486189)
1. Inhibition of Chk1 by the G2 DNA damage checkpoint inhibitor isogranulatimide.
Jiang X; Zhao B; Britton R; Lim LY; Leong D; Sanghera JS; Zhou BB; Piers E; Andersen RJ; Roberge M
Mol Cancer Ther; 2004 Oct; 3(10):1221-7. PubMed ID: 15486189
[TBL] [Abstract][Full Text] [Related]
2. Bis-imide granulatimide analogues as potent Checkpoint 1 kinase inhibitors.
Hénon H; Messaoudi S; Anizon F; Aboab B; Kucharczyk N; Léonce S; Golsteyn RM; Pfeiffer B; Prudhomme M
Eur J Pharmacol; 2007 Jan; 554(2-3):106-12. PubMed ID: 17134696
[TBL] [Abstract][Full Text] [Related]
3. Design of granulatimide and isogranulatimide analogues as potential Chk1 inhibitors: Study of amino-platforms for their synthesis.
Lavrard H; Rodriguez F; Delfourne E
Bioorg Med Chem; 2014 Sep; 22(17):4961-7. PubMed ID: 25047935
[TBL] [Abstract][Full Text] [Related]
4. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01.
Graves PR; Yu L; Schwarz JK; Gales J; Sausville EA; O'Connor PM; Piwnica-Worms H
J Biol Chem; 2000 Feb; 275(8):5600-5. PubMed ID: 10681541
[TBL] [Abstract][Full Text] [Related]
5. A novel indolocarbazole, ICP-1, abrogates DNA damage-induced cell cycle arrest and enhances cytotoxicity: similarities and differences to the cell cycle checkpoint abrogator UCN-01.
Eastman A; Kohn EA; Brown MK; Rathman J; Livingstone M; Blank DH; Gribble GW
Mol Cancer Ther; 2002 Oct; 1(12):1067-78. PubMed ID: 12481430
[TBL] [Abstract][Full Text] [Related]
6. UCN-01 inhibits p53 up-regulation and abrogates gamma-radiation-induced G(2)-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1.
Yu Q; La Rose J; Zhang H; Takemura H; Kohn KW; Pommier Y
Cancer Res; 2002 Oct; 62(20):5743-8. PubMed ID: 12384533
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological activities of isogranulatimide analogues.
Hugon B; Anizon F; Bailly C; Golsteyn RM; Pierré A; Léonce S; Hickman J; Pfeiffer B; Prudhomme M
Bioorg Med Chem; 2007 Sep; 15(17):5965-80. PubMed ID: 17582773
[TBL] [Abstract][Full Text] [Related]
8. CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo.
Tse AN; Rendahl KG; Sheikh T; Cheema H; Aardalen K; Embry M; Ma S; Moler EJ; Ni ZJ; Lopes de Menezes DE; Hibner B; Gesner TG; Schwartz GK
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):591-602. PubMed ID: 17255282
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and in vitro antiproliferative activity of amido and amino analogues of the marine alkaloid isogranulatimide.
Lavrard H; Salvetti B; Mathieu V; Rodriguez F; Kiss R; Delfourne E
ChemMedChem; 2015 Apr; 10(4):607-9. PubMed ID: 25735892
[TBL] [Abstract][Full Text] [Related]
10. Structural basis for Chk1 inhibition by UCN-01.
Zhao B; Bower MJ; McDevitt PJ; Zhao H; Davis ST; Johanson KO; Green SM; Concha NO; Zhou BB
J Biol Chem; 2002 Nov; 277(48):46609-15. PubMed ID: 12244092
[TBL] [Abstract][Full Text] [Related]
11. High-throughput assay for G2 checkpoint inhibitors and identification of the structurally novel compound isogranulatimide.
Roberge M; Berlinck RG; Xu L; Anderson HJ; Lim LY; Curman D; Stringer CM; Friend SH; Davies P; Vincent I; Haggarty SJ; Kelly MT; Britton R; Piers E; Andersen RJ
Cancer Res; 1998 Dec; 58(24):5701-6. PubMed ID: 9865726
[TBL] [Abstract][Full Text] [Related]
12. Marine pyrrolocarbazoles and analogues: synthesis and kinase inhibition.
Deslandes S; Chassaing S; Delfourne E
Mar Drugs; 2009 Dec; 7(4):754-86. PubMed ID: 20098609
[TBL] [Abstract][Full Text] [Related]
13. The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106.
Walton MI; Eve PD; Hayes A; Valenti M; De Haven Brandon A; Box G; Boxall KJ; Aherne GW; Eccles SA; Raynaud FI; Williams DH; Reader JC; Collins I; Garrett MD
Mol Cancer Ther; 2010 Jan; 9(1):89-100. PubMed ID: 20053762
[TBL] [Abstract][Full Text] [Related]
14. Abrogation of Chk1-mediated S/G2 checkpoint by UCN-01 enhances ara-C-induced cytotoxicity in human colon cancer cells.
Shao RG; Cao CX; Pommier Y
Acta Pharmacol Sin; 2004 Jun; 25(6):756-62. PubMed ID: 15169628
[TBL] [Abstract][Full Text] [Related]
15. Structure-based design, synthesis, and biological evaluation of potent and selective macrocyclic checkpoint kinase 1 inhibitors.
Tao ZF; Wang L; Stewart KD; Chen Z; Gu W; Bui MH; Merta P; Zhang H; Kovar P; Johnson E; Park C; Judge R; Rosenberg S; Sowin T; Lin NH
J Med Chem; 2007 Apr; 50(7):1514-27. PubMed ID: 17352464
[TBL] [Abstract][Full Text] [Related]
16. G2 checkpoint kinase inhibitors exert their radiosensitizing effects prior to the G2/M transition.
Sturgeon CM; Roberge M
Cell Cycle; 2007 Mar; 6(5):572-5. PubMed ID: 17351346
[TBL] [Abstract][Full Text] [Related]
17. Hematopoietic cytokines enhance Chk1-dependent G2/M checkpoint activation by etoposide through the Akt/GSK3 pathway to inhibit apoptosis.
Jin ZH; Kurosu T; Yamaguchi M; Arai A; Miura O
Oncogene; 2005 Mar; 24(12):1973-81. PubMed ID: 15674326
[TBL] [Abstract][Full Text] [Related]
18. Chk1 is dispensable for G2 arrest in response to sustained DNA damage when the ATM/p53/p21 pathway is functional.
Lossaint G; Besnard E; Fisher D; Piette J; Dulić V
Oncogene; 2011 Oct; 30(41):4261-74. PubMed ID: 21532626
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the G2 DNA damage checkpoint and of protein kinases Chk1 and Chk2 by the marine sponge alkaloid debromohymenialdisine.
Curman D; Cinel B; Williams DE; Rundle N; Block WD; Goodarzi AA; Hutchins JR; Clarke PR; Zhou BB; Lees-Miller SP; Andersen RJ; Roberge M
J Biol Chem; 2001 May; 276(21):17914-9. PubMed ID: 11279124
[TBL] [Abstract][Full Text] [Related]
20. The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1.
Busby EC; Leistritz DF; Abraham RT; Karnitz LM; Sarkaria JN
Cancer Res; 2000 Apr; 60(8):2108-12. PubMed ID: 10786669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
